<?xml version="1.0" encoding="UTF-8"?>
<p id="p0370">Viral therapeutics to fight COVID-19 includes monoclonal antibodies, repurposed drugs or anti-viral drugs in development stage. To deal with the outbreak immediately, the only option is to repurpose the antiviral drugs due to lack of time by evaluating its safety and efficacy. Among the landscape of therapeutics, based on the broad antiviral spectrum, Remdesivir was considered as first priority. Among the repurposed drugs, the investigation of the anti-retroviral medicine (HIV protease inhibitors), lopinavir/ritonavir, either alone or in combination with Interferon Î² was considered a suitable second option for rapid implementation in clinical trials [
 <xref rid="bb0600" ref-type="bibr">120</xref>]. However, immunotherapies like convalescent sera or other agents are also considered for the treatment option.
</p>
